$RAPT on NASDAQ
March 07, 2024
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 05, 2024
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
February 20, 2024
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
February 13, 2024
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
January 31, 2024
RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 02, 2024
RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
November 27, 2023
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
November 13, 2023
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
November 03, 2023
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC
November 01, 2023
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November
October 18, 2023
RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
August 30, 2023
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
August 11, 2023
RAPT Therapeutics Reports Second Quarter 2023 Financial Results
June 07, 2023
RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
May 25, 2023
RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers
May 11, 2023
RAPT Therapeutics Reports First Quarter 2023 Financial Results
May 03, 2023
RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel
April 26, 2023
RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
March 29, 2023
RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma
March 14, 2023
RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results
February 07, 2023
RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference
January 03, 2023
RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 08, 2022
RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer
November 30, 2022
RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress
November 17, 2022
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
November 17, 2022
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
November 10, 2022
RAPT Therapeutics Reports Third Quarter 2022 Financial Results
November 09, 2022
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences
September 28, 2022
RAPT Therapeutics Strengthens Leadership Team with Two New Key Hires
August 31, 2022
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
August 11, 2022
RAPT Therapeutics Reports Second Quarter 2022 Financial Results
May 25, 2022
RAPT Therapeutics Announces Private Placement Financing of $50 Million
May 23, 2022
RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis
May 11, 2022
RAPT Therapeutics Reports First Quarter 2022 Financial Results
May 04, 2022
RAPT Therapeutics Expands Leadership Team with Multiple Key Hires
March 28, 2022
RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis
March 10, 2022
RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results
February 09, 2022
RAPT Therapeutics to Participate in the 11th Annual SVB Leerink Healthcare Conference
January 04, 2022
RAPT Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
November 10, 2021
RAPT Therapeutics Reports Third Quarter 2021 Financial Results
November 09, 2021
RAPT Therapeutics Appoints Industry Veteran Lori Lyons-Williams to its Board of Directors
November 08, 2021
RAPT Therapeutics to Participate in Upcoming Investor Conferences
October 18, 2021
RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b Data at the 4th Inflammatory Skin Disease Summit
September 30, 2021
RAPT Therapeutics Announces Late-Breaking Oral Presentation of Positive Results from Phase 1b Trial of RPT193 at the 30th European Academy of Dermatology and Venereology Congress
September 20, 2021
RAPT Therapeutics to Present at the 2021 Cantor Virtual Healthcare Conference
September 20, 2021
RAPT Therapeutics to Present RPT193 Phase 1b Data at 30th European Academy of Dermatology and Venereology Congress
September 03, 2021
RAPT Therapeutics to Present at Upcoming Investor Conferences
August 11, 2021
RAPT Therapeutics Reports Second Quarter 2021 Financial Results
June 18, 2021
RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 15, 2021
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
- No Recent Filings Found.
